Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe, Japan and the United States of America (USA).
The aim of this clinical trial is to investigate the safety and pharmacokinetics (the
determination of the concentration of the administered medication in blood over time) of
Pegylated Recombinant Factor IX (nonacog beta pegol) in Non-Bleeding Patients with
Haemophilia B.